The Association Between Scope of Practice Regulations and Nurse Practitioner Prescribing of Buprenorphine After the 2016 Opioid Bill

This article examines the relationship between federal regulations, state scope-of-practice regulations on nurse practitioners (NPs), and buprenorphine prescribing patterns using pharmacy claims data from Optum’s deidentified Clinformatics Data Mart between January 2015 and September 2018. The county-level proportion of patients filling prescriptions written by NPs was low even after the 2016 Comprehensive Addiction and Recovery Act (CARA), 2.7% in states that did not require physician oversight of NPs, and 1.1% in states that did. While analyses in rural counties showed higher rates of buprenorphine prescriptions written by NPs, rates were still considerably low: 3.7% in states with less restrictive regulations and 1.1% in other states. These results indicate that less restrictive scope-of-practice regulations are associated with greater NP prescribing following CARA. The small magnitude of the changes indicates that federal attempts to expand treatment access through CARA have been limited.

[1]  G. Alexander,et al.  Assessment of Filled Buprenorphine Prescriptions for Opioid Use Disorder During the Coronavirus Disease 2019 Pandemic. , 2020, JAMA Internal Medicine.

[2]  Michael Lawrence Barnett,et al.  Treatment of Opioid Use Disorder Among Commercially Insured Patients in the Context of the COVID-19 Pandemic. , 2020, JAMA.

[3]  Douglas R. Roehler,et al.  Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017-2018: A cross-sectional study. , 2020, Drug and alcohol dependence.

[4]  M. Stein,et al.  Buprenorphine waiver uptake among nurse practitioners and physician assistants: The role of existing waivered prescriber supply. , 2020, Journal of substance abuse treatment.

[5]  Darshak M Sanghavi,et al.  Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder , 2020, JAMA network open.

[6]  M. Olfson,et al.  Trends in Buprenorphine Treatment in the United States, 2009-2018. , 2020, JAMA.

[7]  K. Simon,et al.  Comparison of Rural vs Urban Direct-to-Physician Commercial Promotion of Medications for Treating Opioid Use Disorder , 2019, JAMA network open.

[8]  Michael Lawrence Barnett,et al.  In Rural Areas, Buprenorphine Waiver Adoption Since 2017 Driven By Nurse Practitioners And Physician Assistants. , 2019, Health affairs.

[9]  Kristen S. Regenauer,et al.  Applying lessons from task sharing in global mental health to the opioid crisis. , 2019, Journal of consulting and clinical psychology.

[10]  D. Moore.  Nurse Practitioners’ Pivotal Role in Ending the Opioid Epidemic , 2019, The Journal for Nurse Practitioners.

[11]  J. Spetz,et al.  Nurse Practitioner and Physician Assistant Waivers to Prescribe Buprenorphine and State Scope of Practice Restrictions , 2019, JAMA.

[12]  Christopher M. Jones,et al.  Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder , 2018, Addiction.

[13]  D. Patterson,et al.  Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5‐Year Update , 2018, The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association.

[14]  S. Wakeman,et al.  Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use Disorder: X the X Waiver. , 2019, JAMA psychiatry.

[15]  K. N. Theken.  Variability in analgesic response to non-steroidal anti-inflammatory drugs. , 2018, Prostaglandins & other lipid mediators.

[16]  D. Patterson,et al.  Projected Contributions of Nurse Practitioners and Physicians Assistant to Buprenorphine Treatment Services for Opioid Use Disorder in Rural Areas , 2018, Medical care research and review : MCRR.

[17]  Na Wang,et al.  Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality , 2018, Annals of Internal Medicine.

[18]  A. Bohnert,et al.  Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment. , 2018, American journal of preventive medicine.

[19]  B. Andraka-Christou,et al.  A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices. , 2018, The International journal on drug policy.

[20]  Charlene A. Wong,et al.  Common and Costly Hospitalizations Among Insured Young Adults Since the Affordable Care Act. , 2016, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[21]  B. Saloner,et al.  Changes in Substance Abuse Treatment Use Among Individuals With Opioid Use Disorders in the United States, 2004-2013. , 2015, JAMA.

[22]  Christopher M. Jones,et al.  National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. , 2015, American journal of public health.

[23]  M. Doty,et al.  Experiences and Attitudes of Primary Care Providers Under the First Year of ACA Coverage Expansion: Findings from the Kaiser Family Foundation/Commonwealth Fund 2015 National Survey of Primary Care Providers. , 2015, Issue brief.

[24]  W. Ling.  Buprenorphine implant for opioid addiction. , 2012, Pain management.

[25]  D. D. Ingram,et al.  NCHS urban-rural classification scheme for counties. , 2012, Vital and health statistics. Series 2, Data evaluation and methods research.

[26]  J. Trafton,et al.  Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. , 2011, Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors.